Panic Disorders Market Report 2026

The panic disorders market size has grown strongly in recent years. It will grow from $11.15 billion in 2025 to $11.73 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to limited awareness of panic disorders, reliance on traditional in-person therapy, high cost of medications, fragmented mental healthcare infrastructure, low adoption of digital therapy tools.

The panic disorders market size is expected to see strong growth in the next few years. It will grow to $15 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing prevalence of anxiety and panic disorders, growth in telepsychiatry adoption, advancements in virtual reality and neurofeedback therapies, expansion of online pharmacy and hospital distribution channels, rising demand for personalized mental healthcare plans. Major trends in the forecast period include rising adoption of telepsychiatry and mobile mental health applications, integration of virtual reality therapy for anxiety disorders, increasing use of biofeedback and neurofeedback techniques, growth in personalized medication plans for panic disorders, expansion of mental healthcare facilities and hospital services.

The growing adoption of telehealth is expected to drive growth in the panic disorders market going forward. Telehealth leverages electronic communication technologies, including videoconferencing, phone calls, and secure messaging, to deliver remote healthcare services and consultations. This approach enables psychotherapy and counseling for individuals with panic disorders, allowing therapists to conduct one-on-one sessions, group therapy, or support groups via secure videoconferencing platforms. For instance, in April 2023, FAIR Health Inc., a US-based non-profit organization, reported a 7.3% national increase in telehealth usage, rising from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. Therefore, the increasing use of telehealth is fueling growth in the panic disorders market.

Companies in this market are also focusing on the development of advanced medications, such as extended-release capsules, to maintain a competitive edge. Extended-release capsules gradually release the active ingredient over 12 to 24 hours, offering sustained treatment for conditions requiring long-term medication. For example, in May 2023, Granules India Ltd., an India-based pharmaceutical company, received abbreviated new drug application (ANDA) approval from the US FDA for venlafaxine hydrochloride extended-release capsules. These capsules demonstrated bioequivalence with the reference-listed drug Effexor XR Extended-Release Capsules, manufactured by Upjohn US 2 LLC. Venlafaxine HCl extended-release capsules are prescribed for generalized anxiety disorder (GAD), major depressive disorder (MDD), panic disorder (PD), and social anxiety disorder (SAD), working by increasing serotonin and norepinephrine levels in the brain. The typical starting dose is 75 mg per day, adjustable by a physician as needed.

In February 2023, Vistagen Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, acquired Pherin Pharmaceuticals Inc. for an undisclosed amount. This acquisition allows Vistagen to develop and commercialize innovative treatments for depression and anxiety disorders, including panic disorders. The deal is expected to strengthen the commercial potential of each drug candidate. Pherin Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in drug development for panic disorders.

Major companies operating in the panic disorders market are F. Hoffmann‑La Roche Ltd, Sanofi S.A, Bristol‑Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, Mylan N.V., Pfizer Inc, Sun Pharmaceutical Industries Ltd, H. Lundbeck A/S, Neurocrine Biosciences Inc, Neuraxpharm, Actavis Plc, Sumitomo Pharma Co Ltd, LIFECARE NEURO PRODUCTS LTD, Merck & Co Inc, Johnson & Johnson, Novartis AG, Otsuka Pharmaceutical Co Ltd.

North America was the largest region in the panic disorders market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the panic disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the panic disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the panic disorders market by raising the cost of imported medications, neurofeedback devices, and virtual reality therapy systems. Hospital pharmacies, retail pharmacies, and online pharmacy platforms in north america, europe, and asia-pacific are most affected due to dependence on imported treatments. While tariffs create cost pressures, they also promote domestic production, stimulate innovation in digital mental health solutions, and improve local availability of telepsychiatry and therapeutic devices.

The panic disorders market research report is one of a series of new reports that provides panic disorders market statistics, including panic disorders industry global market size, regional shares, competitors with a panic disorders market share, detailed panic disorders market segments, market trends and opportunities, and any further data you may need to thrive in the panic disorders industry. This panic disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Panic disorder is a type of anxiety disorder marked by sudden and recurrent episodes of intense fear or discomfort, often accompanied by physical symptoms such as shortness of breath, chest pain, heart palpitations, nausea, and abdominal distress. Treatment generally involves a combination of medication and psychotherapy.

The main types of panic-related disorders include agoraphobia, social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), bipolar disorder, post-traumatic stress disorder (PTSD), and major depressive disorder. Agoraphobia involves the intentional avoidance of places or situations that may trigger panic symptoms or feelings of entrapment, helplessness, or social discomfort. Treatments include medications such as beta-blockers, serotonin and norepinephrine reuptake inhibitors (SNRIs), benzodiazepines, anti-epileptic drugs, and others. These are administered through oral, parenteral, and other routes, and are distributed via hospital pharmacies, retail pharmacies, and online pharmacy platforms.

The panic disorder market consists of revenue earned by entities by providing services such as physical tests, cognitive behavioral therapy (CBT), and psychological evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The panic disorder market includes sales of tablets and injectables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.